📊 CYDY Key Takeaways
Is CytoDyn Inc. (CYDY) a Good Investment?
CytoDyn exhibits severe financial distress with negative stockholders' equity of -$119.7M, indicating the company is technically insolvent. The company has zero revenue, massive operating losses of -$26.6M, and is burning cash at -$6.8M annually with only $5.0M in cash reserves. The balance sheet shows liabilities exceeding assets by $119.7M, creating an unsustainable capital structure.
CytoDyn's fundamentals are extremely weak: it has no revenue, continues to post large operating and net losses, and carries a deeply negative equity position with liabilities far exceeding assets. Although the latest period shows improved net loss versus the prior year, the company remains heavily cash-burning and severely constrained by poor liquidity, making the quality and durability of any turnaround highly uncertain.
CytoDyn Inc. Key Strengths (CYDY)
- Slight improvement in net loss year-over-year (loss narrowed by 65.6%, though still deeply negative)
- Minimal capital expenditure ($30K) suggests company has eliminated discretionary spending
- Still maintains $5.0M in cash reserves providing limited runway
- Net loss improved materially year over year, indicating some cost reduction or non-operating improvement
- The business has modest cash on hand relative to its near-term operating needs
- Capital expenditure requirements are minimal, which limits additional cash strain from fixed-asset investment
CYDY Stock Risks: CytoDyn Inc. Investment Risks
- Negative stockholders' equity of -$119.7M indicates technical insolvency and high bankruptcy risk
- Zero revenue generation with no apparent path to commercialization
- Massive cash burn of -$6.8M annually against only $5.0M in cash reserves (less than 1 year of runway)
- Current ratio of 0.10x indicates severe liquidity crisis and inability to meet short-term obligations
- Operating losses of -$26.6M with no revenue offsetting expenses
- Long-term debt of $42.2M on nearly-worthless asset base with negative equity
- Zero revenue means the company currently lacks a proven operating earnings base
- Negative stockholders equity and a 0.10x current ratio indicate severe balance-sheet and liquidity stress
- Ongoing negative operating cash flow and meaningful long-term debt raise financing and going-concern risk
Key Metrics to Watch
- Cash burn rate and remaining months of cash runway
- Whether company achieves any revenue or FDA approval for pipeline assets
- Debt restructuring or refinancing announcements
- Additional equity dilution from capital raises needed for survival
- Quarterly revenue generation or commercialization progress
- Cash burn relative to cash balance and any changes in current liabilities/debt burden
CytoDyn Inc. (CYDY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CYDY Profit Margin, ROE & Profitability Analysis
CYDY vs Healthcare Sector: How CytoDyn Inc. Compares
How CytoDyn Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CytoDyn Inc. Stock Overvalued? CYDY Valuation Analysis 2026
Based on fundamental analysis, CytoDyn Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CytoDyn Inc. Balance Sheet: CYDY Debt, Cash & Liquidity
CYDY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CytoDyn Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.05 indicates the company is currently unprofitable.
CYDY Revenue Growth, EPS Growth & YoY Performance
CYDY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $266.0K | -$13.7M | $-0.02 |
| Q2 2023 | $225.0K | -$21.0M | $-0.03 |
| Q1 2023 | $41.0K | -$21.0M | $-0.03 |
| Q3 2021 | N/A | -$30.8M | $-0.05 |
| Q2 2021 | N/A | -$30.8M | $-0.05 |
| Q1 2021 | N/A | -$30.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CytoDyn Inc. Dividends, Buybacks & Capital Allocation
CYDY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CytoDyn Inc. (CIK: 0001175680)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYDY
What is the AI rating for CYDY?
CytoDyn Inc. (CYDY) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYDY's key strengths?
Claude: Slight improvement in net loss year-over-year (loss narrowed by 65.6%, though still deeply negative). Minimal capital expenditure ($30K) suggests company has eliminated discretionary spending. ChatGPT: Net loss improved materially year over year, indicating some cost reduction or non-operating improvement. The business has modest cash on hand relative to its near-term operating needs.
What are the risks of investing in CYDY?
Claude: Negative stockholders' equity of -$119.7M indicates technical insolvency and high bankruptcy risk. Zero revenue generation with no apparent path to commercialization. ChatGPT: Zero revenue means the company currently lacks a proven operating earnings base. Negative stockholders equity and a 0.10x current ratio indicate severe balance-sheet and liquidity stress.
What is CYDY's revenue and growth?
CytoDyn Inc. reported revenue of $0.0.
Does CYDY pay dividends?
CytoDyn Inc. does not currently pay dividends.
Where can I find CYDY SEC filings?
Official SEC filings for CytoDyn Inc. (CIK: 0001175680) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYDY's EPS?
CytoDyn Inc. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CYDY's fundamental grade?
Based on our AI fundamental analysis in June 2026, CytoDyn Inc. has a D grade with 94% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CYDY stock overvalued or undervalued?
Valuation metrics for CYDY: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CYDY's AI grade for 2026?
Our dual AI analysis gives CytoDyn Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CYDY's free cash flow?
CytoDyn Inc.'s operating cash flow is $-6.8M, with capital expenditures of $30.0K.
How does CYDY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.10 (avg: 2).